Physician profile
Scott Cole
NPI 1255622940
$527.73
in general payments reported to CMS, 2019-2025
12 companies · $73.50 in 2025
The $73.50 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.92 · 2022: $38.48 · 2023: $116 · 2024: $201 · 2025: $73.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $158.99 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $108.77 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $42.63 | 2024 | Vabysmo |
| Alcon Vision LLC | $42.60 | 2024-2025 | Rocklatan, Simbrinza |
| Carl Zeiss Meditec USA, INC. | $30.00 | 2025 | Cirrus Hd-Oct |
| Sandoz INC. | $27.60 | 2024 | Cimerli |
| Biotissue Holdings INC. | $24.85 | 2023 | |
| Dompe US, INC. | $23.33 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $22.35 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.12 | 2023 | Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $15.69 | 2023 | Infuse |
| Oyster Point Pharma, INC. | $13.80 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.